SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study)
Abstract Immunogenicity following inactivated SARS-CoV-2 vaccination among solid organ transplant recipients has not been assessed. Seventy-five patients (37 kidney transplant [KT] recipients and 38 non-transplant controls) received two doses, at 4-week intervals, of an inactivated whole-virus SARS-CoV-2 vaccine. SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity (CMI) were measured before, 4 weeks post-first dose, and 2 weeks post-second dose. The median age of KT recipients was 50 years (IQR, 42–54) and 89% were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median time since transplant was 4.5 years (IQR, 2–9.5). Among 35 KT patients, anti-RBD IgG titer after vaccination was not significantly different to baseline, but was significantly lower than in controls (7.8 [95%CI 0.2–15.5] vs 2,691 [95%CI 1,581–3,802], p<0.001) as well as the percentage of surrogate virus neutralizing antibody inhibition (2 [95% CI −1-6] vs 71 [95%CI 61–81], p<0.001). However, the mean of SARS-CoV-2 mixed peptides-specific T-cell responses measured by enzyme-linked immunospot assays was significantly increased compared with baseline (66 [95%CI 36–99] vs. 34 [95%CI 19–50] T-cells/106PBMCs, p=0.02) and comparable to that in controls. Our findings revealed weak HMI and marginal CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccine. (Thai Clinical Trials Registry, TCTR20210226002)..
Medienart: |
Preprint |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
bioRxiv.org - (2023) vom: 06. Nov. Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bruminhent, Jackrapong [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
doi: |
10.1101/2021.08.02.21261095 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
XBI032328885 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | XBI032328885 | ||
003 | DE-627 | ||
005 | 20231205150325.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210805s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1101/2021.08.02.21261095 |2 doi | |
035 | |a (DE-627)XBI032328885 | ||
035 | |a (biorXiv)10.1101/2021.08.02.21261095 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bruminhent, Jackrapong |e verfasserin |0 (orcid)0000-0003-0930-8936 |4 aut | |
245 | 1 | 0 | |a SARS-CoV-2-specific Humoral and Cell-mediated Immune Responses after Immunization with Inactivated COVID-19 Vaccine in Kidney Transplant Recipients (CVIM 1 Study) |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Abstract Immunogenicity following inactivated SARS-CoV-2 vaccination among solid organ transplant recipients has not been assessed. Seventy-five patients (37 kidney transplant [KT] recipients and 38 non-transplant controls) received two doses, at 4-week intervals, of an inactivated whole-virus SARS-CoV-2 vaccine. SARS-CoV-2-specific humoral (HMI) and cell-mediated immunity (CMI) were measured before, 4 weeks post-first dose, and 2 weeks post-second dose. The median age of KT recipients was 50 years (IQR, 42–54) and 89% were receiving calcineurin inhibitors/mycophenolate/corticosteroid regimens. The median time since transplant was 4.5 years (IQR, 2–9.5). Among 35 KT patients, anti-RBD IgG titer after vaccination was not significantly different to baseline, but was significantly lower than in controls (7.8 [95%CI 0.2–15.5] vs 2,691 [95%CI 1,581–3,802], p<0.001) as well as the percentage of surrogate virus neutralizing antibody inhibition (2 [95% CI −1-6] vs 71 [95%CI 61–81], p<0.001). However, the mean of SARS-CoV-2 mixed peptides-specific T-cell responses measured by enzyme-linked immunospot assays was significantly increased compared with baseline (66 [95%CI 36–99] vs. 34 [95%CI 19–50] T-cells/106PBMCs, p=0.02) and comparable to that in controls. Our findings revealed weak HMI and marginal CMI responses in fully vaccinated KT recipients receiving inactivated SARS-CoV-2 vaccine. (Thai Clinical Trials Registry, TCTR20210226002). | ||
650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
700 | 1 | |a Sethaudom, Chavachol |4 aut | |
700 | 1 | |a Chaumdee, Pongsathon |4 aut | |
700 | 1 | |a Boongird, Sarinya |4 aut | |
700 | 1 | |a Kiertiburanakul, Sasisopin |4 aut | |
700 | 1 | |a Malathum, Kumthorn |4 aut | |
700 | 1 | |a Nongnuch, Arkom |4 aut | |
700 | 1 | |a Phuphuakrat, Angsana |4 aut | |
700 | 1 | |a Jirasiritham, Sopon |4 aut | |
700 | 1 | |a Janphram, Chitimaporn |4 aut | |
700 | 1 | |a Thotsiri, Sansanee |4 aut | |
700 | 1 | |a Upama, Supparat |4 aut | |
700 | 1 | |a Assanatham, Montira |4 aut | |
773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 06. Nov. |
773 | 1 | 8 | |g year:2023 |g day:06 |g month:11 |
856 | 4 | 0 | |u https://doi.org/10.1111/ajt.16867 |z lizenzpflichtig |3 Volltext |
856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.08.02.21261095 |z kostenfrei |3 Volltext |
912 | |a GBV_XBI | ||
951 | |a AR | ||
952 | |j 2023 |b 06 |c 11 |